Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2018

View Archived Issues

Brain sleepiness signature, links to memory identified

FDA issues complete response letter for Duobrii lotion

Amgen initiates phase I trial of AMG-119 in small cell lung cancer

Safety run-in results presented from phase III ANDROMEDA study on daratumumab

Phase II results for talimogene laherparepvec plus pembrolizumab in patients with sarcoma

Forge Therapeutics LpxC inhibitor shows activity in vitro, in vivo and in combination

FDA grants fast track designation to mirvetuximab soravtansine in platinum-resistant ovarian cancer

Catalyst offers update from Cohort 6 in phase I/II trial of CB-2679d for hemophilia B

Agios initiates phase III ACTIVATE study of AG-348 in pyruvate kinase deficiency

Rhythm announces new topline clinical data for setmelanotide in rare genetic disorders of obesity

MXRA8, a drug-targetable receptor for chikunguya and other arthritogenic alphaviruses

Cognition Therapeutics initiates SPARC trial of Elayta in Alzheimer's disease

Clover initiates phase I trial of SCB-313 for malignant ascites

Sanofi completes acquisition of Ablynx

Roche and Foundation Medicine enter definitive merger agreement

FDA removes clinical hold on IGNITE DMD study of SGT-001

XMT-1522 demonstrates safety and preliminary efficacy in phase I study

Wellcome Trust grant supports Karuna's development of KarXT for schizophrenia

Xavier University of Louisiana divulges androgen receptor signaling inhibitors

Hedgehog pathway modulators patented by Development Center for Biotechnology, DCB-USA

Shanghai Institute of Materia Medica discovers BTK inhibitors

Glycogen synthase kinase 3 inhibitors patented by Bristol-Myers Squibb

FDA places clinical hold on phase I trial evaluating Ziopharm's CD19-targeted CAR T therapy

Alexion submits U.S. BLA for ALXN-1210 to treat PNH

First-in-human results reported for MK-1248 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...